Google
AAPG 株価分析 — Ascentage Pharma Group International (Healthcare >> Biotechnology)
AAPG に関するよくある質問
AAPGのROE（自己資本利益率）は？
Ascentage Pharma Group InternationalのROEは-184.04%です。
AAPGの配当利回りは？
Ascentage Pharma Group Internationalの配当利回りは0.00%です。
AAPGの品質スコア（Quality Score）は？
当社のAIはAAPGの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
AAPGは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
AAPGはどのセクターに属しますか？
Ascentage Pharma Group InternationalはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
AAPG AI Analysis Summary
Our AI summary for AAPG: Ascentage Pharma Group International (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -184.04%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.69
Price
-0.12
(-0.68%)
Day Change
|
|
|---|
AAPG, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.69 |
| PBV / Sector |
1.17 / 44,022.72
GREAT
|
| Earning Per Share | -25.95 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-05 07:59:45 |
| Symbol | AAPG |
| Name | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 93.34 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,568.53 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Suzhou Industrial Park, Suzhou, China, 215000
Phone: 86 512 8555 7777
Website: https://www.ascentage.cn
Employees: 767
Sector: Healthcare >> Biotechnology
Description: Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
